IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Greenleaf Trust

Greenleaf Trust boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 3.5% in the 3rd quarter, Holdings Channel reports. The firm owned 3,286 shares of the medical research company’s stock after acquiring an additional 111 shares during the quarter. Greenleaf Trust’s holdings in IQVIA were worth $779,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Lecap Asset Management Ltd. raised its stake in IQVIA by 411.5% in the 3rd quarter. Lecap Asset Management Ltd. now owns 11,738 shares of the medical research company’s stock valued at $2,782,000 after purchasing an additional 9,443 shares during the last quarter. Community Trust & Investment Co. increased its stake in shares of IQVIA by 1.1% in the 3rd quarter. Community Trust & Investment Co. now owns 73,606 shares of the medical research company’s stock worth $17,442,000 after acquiring an additional 829 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of IQVIA by 13.2% in the 3rd quarter. Private Advisor Group LLC now owns 5,746 shares of the medical research company’s stock worth $1,362,000 after acquiring an additional 668 shares during the last quarter. Eastern Bank increased its stake in shares of IQVIA by 0.3% in the 3rd quarter. Eastern Bank now owns 60,205 shares of the medical research company’s stock worth $14,267,000 after acquiring an additional 151 shares during the last quarter. Finally, Signaturefd LLC increased its stake in shares of IQVIA by 5.0% in the 3rd quarter. Signaturefd LLC now owns 2,548 shares of the medical research company’s stock worth $604,000 after acquiring an additional 121 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQVIA stock opened at $211.71 on Friday. The business has a 50-day moving average of $238.71 and a 200 day moving average of $230.92. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The stock has a market capitalization of $38.59 billion, a price-to-earnings ratio of 27.49, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.22 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on IQV shares. Barclays cut their target price on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Morgan Stanley raised their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Truist Financial cut their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Argus upgraded IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $267.27.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.